Budget impact analysis of botulinum toxin A therapy for upper limb spasticity in the United Kingdom

References

• BandiSWardAB2010SpasticityStoneJHBlouinMInternational Encyclopedia of Rehabilitation http://cirrie.buffalo.edu/encyclopedia/en/article/32/Accessed February 18, 2015
   Google Scholar
• BuchananRJChakravortyBJTyryTHatcherWVollmerTAge- related comparisons of people with multiple sclerosis: demographic, disease, and treatment characteristicsNeuroRehabilitation200925427127820037220
   PubMed Web of Science ®Google Scholar
• LawrensonRWyndaeleJ-JVlachonikolisIFarmerCGlickmanSRenal failure in patients with neurogenic lower urinary tract dysfunctionNeuroepidemiology200120213814311359083
   PubMed Web of Science ®Google Scholar
• WatkinsCLLeathleyMJGregsonJMMooreAPSmithTLSharmaAKPrevalence of spasticity post strokeClin Rehabil200216551552212194622
   PubMed Web of Science ®Google Scholar
• IvanhoeCBReistetterTASpasticity: the misunderstood part of the upper motor neuron syndromeAmerican Journal of Physical Medicine & Rehabilitation20048310S3S915448572
   PubMed Web of Science ®Google Scholar
• DoanQVBrashearAGillardPJRelationship between disability and health-related quality of life and caregiver burden in patients with upper limb poststroke spasticityPM R20124141022200567
   PubMedGoogle Scholar
• EsquenaziAThe human and economic burden of poststroke spasticity and muscle overactivityJ Clin Outcomes Manag2011181607614
   Google Scholar
• LundströmESmitsABorgJTeréntAFour-fold increase in direct costs of stroke survivors with spasticity compared with stroke survivors without spasticity: the first year after the eventStroke201041231932420044535
   PubMed Web of Science ®Google Scholar
• DoanQVGillardPBrashearACost-effectiveness of onabotulinumtoxinA for the treatment of wrist and hand disability due to upper-limb post-stroke spasticity in ScotlandEur J Neurol201320577378023278954
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care ExcellenceSpasticityChildren and Young People with Nonprogressive Brain Disorders: Management of Spasticity and Co-existing Motor Disorders and their Early Musculoskeletal Complications (CG145)ManchesterNational Institute for Health and Care Excellence2012
   Google Scholar
• BakheitAMThilmannAFWardABA randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after strokeStroke200031102402240611022071
   PubMed Web of Science ®Google Scholar
• BhaktaBBCozensJABamfordJMChamberlainMAUse of botulinum toxin in stroke patients with severe upper limb spasticityJ Neurol Neurosurg Psychiatry199661130358676154
   PubMed Web of Science ®Google Scholar
• BrashearAGordonMFElovicEBotox Post-Stroke Spasticity Study GroupIntramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a strokeN Engl J Med2002347639540012167681
   PubMed Web of Science ®Google Scholar
• CatyGDDetrembleurCBleyenheuftCDeltombeTLejeuneTMEffect of upper limb botulinum toxin injections on impairment, activity, participation, and quality of life among stroke patientsStroke20094072589259119407231
   PubMed Web of Science ®Google Scholar
• FrancisHPWadeDTTurner-StokesLKingswellRSDottCSCoxonEADoes reducing spasticity translate into functional benefit? An exploratory meta-analysisJ Neurol Neurosurg Psychiatry200475111547155115489384
   PubMed Web of Science ®Google Scholar
• LukbanMBRosalesRLDresslerDEffectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidenceJ Neural Transm2009116331933119142573
   PubMed Web of Science ®Google Scholar
• OzcakirSSivriogluKBotulinum toxin in poststroke spasticityClin Med Res20075213213817607049
   PubMedGoogle Scholar
• ShawLRodgersHPriceCBoTULS investigatorsBoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type AHealth Technol Assess201014261113iii20515600
   PubMed Web of Science ®Google Scholar
• WardARobertsGWarnerJGillardSCost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticityJ Rehabil Med200537425225716024483
   PubMed Web of Science ®Google Scholar
• Royal College of PhysiciansBritish Society of Rehabilitation MedicineChartered Society of PhysiotherapyAssociation of Chartered Physiotherapists Interested in NeurologySpasticity in Adults: Management Using Botulinum Toxin National GuidelinesLondonRoyal College of Physicians2009
   Google Scholar
• TimothyWSmithBATierceJCDesigning and developing budget impact models suited for global adaptationISPOR Connections2006124710
   Google Scholar
• HesseSReiterFKonradMJahnkeMTBotulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trialClin Rehabil19981253813889796928
   PubMed Web of Science ®Google Scholar
• SimpsonDMAlexanderDNO’BrienCFBotulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trialNeurology1996465130613108628472
   PubMed Web of Science ®Google Scholar
• BNF: Joint Formulary CommitteeBritish National Formulary (online)LondonBMJ Group and Pharmaceutical Presshttp://www.medicinescomplete.comAccessed December 2012
   Google Scholar
• PSSRU: Unit Costs of Health and Social Care 2011. Compiled by L CurtisPSSRUhttp://www.pssru.ac.uk/project-pages/unit-costs/2011/index.phpAccessed December 2012
   Google Scholar
• NHS reference costs: NHS reference costs – 2010–2011http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/Publications-PolicyAndGuidance/DH_131140Accessed December 2012
   Google Scholar
• Botox 100 units [Summary of Product Characteristics]Datapharm2013 [updated May 22, 2104]. Available from: http://www.medicines.org.uk/emc/medicine/112/SPC/BOTOX+100+UnitsAccessed January 26, 2015
   Google Scholar
• Dysport 300 units, Dysport 500 units [Summary of Product Characteristics]Datapharm2012[updated December 23, 2013]. Available from: http://www.medicines.org.uk/emc/medicine/870Accessed January 26, 2015
   Google Scholar
• Xeomin 100 units, [Summary of Product Characteristics]Datapharm2012[updated June 30, 2014]. Available from: http://www.medicines.org.uk/emc/medicine/20666/SPC/Xeomin+100+UnitsAccessed 26, 2015
   Google Scholar
• BuxtonMJDrummondMFVan HoutBAModelling in economic evaluation: an unavoidable fact of lifeHealth Econ1997632172279226140
   PubMed Web of Science ®Google Scholar
• Turner-StokesLFheodoroffKJacintoJMaisonobePResults from the Upper Limb International Spasticity Study-II (ULISII): a large, international, prospective cohort study investigating practice and goal attainment following treatment with botulinum toxin A in real-life clinical managementBMJ Open201336e002771
   PubMed Web of Science ®Google Scholar
• DinetJLambrelliDBalcaitieneJEconomic modeling of the use of botulinum toxin A in a homogenous patient population based on real-life clinical practice: Ulis-Ii (the Upper Limb International Spasticity Study)Value Health2014177A377
   Web of Science ®Google Scholar
• BeechamJPerkinsMSnellTKnappMTreatment paths and costs for young adults with acquired brain injury in the United KingdomBrain Inj2009231303819096972
   PubMed Web of Science ®Google Scholar
• World Health OrganizationAtlas: Multiple Sclerosis Resources in the World 2008GenevaWorld Health Organization2008
   Google Scholar
• Yeargin-AllsoppMVan Naarden BraunKDoernbergNSBenedictREKirbyRSDurkinMSPrevalence of cerebral palsy in 8-year-old children in three areas of the United States in 2002: a multisite collaborationPediatrics2008121354755418310204
   PubMed Web of Science ®Google Scholar